SCHEDULE 13G/A: Wellington Management Divests Myriad Genetics Stake

Wellington Management Group and its affiliates have reported a 0.0% beneficial ownership in Myriad Genetics, Inc. common stock, indicating a complete divestment or reduction below reporting thresholds.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP are the reporting entities.
• The reporting entities collectively hold 0.00 shares of Myriad Genetics, Inc. common stock.
• This represents 0.0% of the class of securities as of June 30, 2025.
• The filing indicates a complete divestment or reduction of holdings below the 5% reporting threshold by Wellington Management Group and its affiliates.
• The securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of Myriad Genetics, Inc.

Sentiment

Score: 3

Explanation: The filing indicates a complete divestment by Wellington Management Group and its affiliates, which can be interpreted as a negative signal regarding their outlook on Myriad Genetics, Inc.

Positives

• No direct positives for Myriad Genetics, Inc. are indicated in this filing, as it reports a complete divestment by the reporting entities.

Negatives

• Wellington Management Group LLP and its affiliates have reduced their beneficial ownership in Myriad Genetics, Inc. common stock to 0.0%, indicating a complete divestment or reduction below the 5% reporting threshold.

Risks

• No specific risks for Myriad Genetics, Inc. are mentioned within this beneficial ownership filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Myriad Genetics, Inc. or its future performance.

Management Comments

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This is a routine institutional ownership disclosure. The divestment by a major asset manager like Wellington Management Group could be interpreted by the market as a change in investment sentiment towards Myriad Genetics, Inc. or the broader diagnostics industry, though the specific reasons for the divestment are not disclosed in this filing.

Comparison to Industry Standards

• Not applicable, as this filing reports a change in institutional ownership rather than operational or financial performance metrics that can be benchmarked against industry standards or competitors.

Stakeholder Impact

• Shareholders of Myriad Genetics, Inc. may react to the news of a major institutional investor divesting its entire stake, potentially influencing market sentiment and share price.
• Investment professionals may re-evaluate their positions in Myriad Genetics, Inc. based on this institutional ownership change.

Next Steps

• No specific future actions, events, or milestones for Myriad Genetics, Inc. are mentioned in this filing.

Key Dates

Recommendation

The complete divestment of Myriad Genetics, Inc. common stock by Wellington Management Group and its affiliates, as reported in this Schedule 13G, suggests a significant loss of institutional confidence or a strategic shift away from the company. Such a move by a major asset manager often precedes or accompanies negative market sentiment, making a 'sell' recommendation prudent for investors to mitigate potential downside risk.

Keywords

Myriad Genetics, MYGN, Wellington Management, Schedule 13G, beneficial ownership, common stock, institutional ownership, divestment